A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 - Estimating occupancy in the absence of a reference region

NeuroImage

Volumn 82, Issue , 2013, Pages 160-169

  Kågedal, Matts ^a,c   Cselényi, Zsolt ^a   Nyberg, Svante ^a   Raboisson, Patrick ^a   Ståhle, Lars ^a   Stenkrona, Per ^b   Varnäs, Katarina ^b   Halldin, Christer ^b   Hooker, Andrew C ^c   Karlsson, Mats O ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

11C ABP688; MGluR5 receptor; Nonlinear mixed effects modelling; Positron emission tomography; Receptor occupancy

Indexed keywords

ABP 688 C 11; AZD 2066; CARBON 11; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; RADIOLIGAND; UNCLASSIFIED DRUG;

ARTICLE; ASTHENIA; ATTENTION DISTURBANCE; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; CONTROLLED STUDY; DIZZINESS; DRUG BINDING SITE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG UPTAKE; DRUNK SENSATION; ERYTHROCYTE; FEMALE; GRAY MATTER; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; ILLUSION; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SIDE EFFECT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

[(11)C]-ABP688; MGLUR5 RECEPTOR; NONLINEAR MIXED EFFECTS MODELLING; POSITRON EMISSION TOMOGRAPHY; RECEPTOR OCCUPANCY;

ADULT; ANALGESICS; ANTI-ANXIETY AGENTS; BRAIN; CARBON RADIOISOTOPES; HEALTHY VOLUNTEERS; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; OXIMES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTOR, METABOTROPIC GLUTAMATE 5; TRIAZOLES; YOUNG ADULT;

EID: 84879702095     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2013.05.006     Document Type: Article

References (46)

1. Aarons L. Population approaches/sparse data analysis for human variability in kinetics and dynamics. Environ. Toxicol. Pharmacol. 1996, 2:197-199.
2. 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J. Nucl. Med. 2006, 47:698-705.
3. 11C-ABP688. J. Nucl. Med. 2007, 48:247-252.
4. Anderson J.J., Rao S.P., Rowe B., Giracello D.R., Holtz G., Chapman D.F., Tehrani L., Bradbury M.J., Cosford N.D., Varney M.A. [3H]methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: In vitro and in vivo characterization. J. Pharmacol. Exp. Ther. 2002, 303:1044-1051.
5. NONMEM User's Guide 1989-2006, Icon Development Solutions, Ellicott City, Maryland, USA. S. Beal, L.B. Sheiner, A. Boeckmann (Eds.).
6. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27(7):370-377. (Jul).
7. Berg D., Godau J., Trenkwalder C., Eggert K., Csoti I., Storch A., Huber H., Morelli-Canelo M., Stamelou M., Ries V., Wolz M., Schneider C., Di Paolo T., Gasparini F., Hariry S., Vandemeulebroecke M., Abi-Saab W., Cooke K., Johns D., Gomez-Mancilla B. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov. Disord. 2011, 26(7):1243-1250.
8. Berges A., Zamuner S., Laurijssens B., Gunn R., Cunningham V., Chen C. Using VT (Total Volume of Distribution from PET) in Estimating the PK-Receptor Occupancy Relationship in the Absence of Reference Regions 2008, 17. (Abstr 1398 [www.page-meeting.org/?abstract=1398]).
9. Bergström M., Boethius J., Eriksson L., Greitz T., Ribbe T., Widén L. Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. J. Comput. Assist. Tomogr. 1981, 5:136-141.
10. Brodkin J., Busse C., Sukoff S.J., Varney M.A. Anxiolytic-like activity of the mGluR5 antagonist MPEP: a comparison with diazepam and buspirone. Pharmacol. Biochem. Behav. 2001, 73(2):359-366.
11. Chiamulera C., Epping-Jordan M.P., Zocchi A., Marcon C., Cottiny C., Tacconi S., Corsi M., Orzi F., Conquet F. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 2001, 4(9):873-874. (Sep).
12. 11C]WAY 100635. NeuroImage 2006, 32:1690-1708.
13. Cunningham V.J., Rabiner E.A., Matthews J., Gunn R., Zamuner S., Gee A. Kinetic analysis of neuroreceptor binding using PET. Int. Congr. Ser. 2004, 1265:12-24.
14. Cunningham V.J., Rabiner E.A., Slifstein M., Laruelle M., Gunn R. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J. Cereb. Blood Flow Metab. 2010, 30(1):46-50. (1).
15. 11C] ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons. Eur. J. Nucl. Med. Mol. Imaging 2011, 38(6):1083-1094.
16. 11C] ABP688. J. Cereb. Blood Flow Metab. 2011, 31:2169-2180.
17. Eriksson L., Holte S., Bohm C., Kesselberg M., Hovander B. Automated blood sampling systems for positron emission tomography. IEEE Trans. Nucl. Sci. 1988, 35:703-707.
18. Farde L., Eriksson L., Blomquist G., Halldin C. Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J. Cereb. Blood Flow Metab. 1989, 9(5):696-708.
19. Gasparini F., Lingenhohl K., Stoehr N., et al. 2-methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999, 38:1493-1503.
20. Halldin C., Farde L., Högberg T., Mohell N., Hall H., Suhara T., Karlsson P., Nakashima Y., Swahn C.G. Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J. Nucl. Med. 1995, 36(7):1275-1281. (Jul).
21. Hintermann S., Vranesic I., Allgeier H., Brülisauer A., Hoyer D., Lemaire M., Moenius T., Urwyler S., Whitebread S., Gasparini F., Auberson Y.P. ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: Identification, in vitro pharmacology, pharmacokinetic and biodistribution studies. Bioorg. Med. Chem. 2007, 15:903-914.
22. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
23. Johnson K.A., Conn P.J., Niswender C.M. Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol. Disord. Drug Targets 2009, 8(6):475-491. (Dec).
24. Jonsson E.N., Karlsson M.O. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Prog. Biomed. 1999, 58:51-64.
25. Jonzon B., Butler S., Karlsten R., Malamut R., Ståhle L., Huizar K., Stacey B.R. Efficacy and safety of the mGluR5 antagonist AZD2066 in peripheral neuropathic pain patients with mechanical hypersensitivity (NPMH): results of a Phase IIa randomised, doubleblind, placebo-controlled study 2012, Abstract of the 14thWorld Congress on Pain, Milan, PT427.
26. Kågedal M., Cselényi Z., Nyberg S., Jönsson S., Raboisson P., Stenkrona P., Hooker A.C., Karlsson M.O. Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers. NeuroImage 2012, 61:849-856.
27. Karlsten R., Malamut R., Jonzon B., Ståhle L., Huizar K., Argoff C.E. Efficacy and safety of the mGluR5 antagonist AZD2066 in painful diabetes neuropathy (PDN): Results of a phase IIa randomised, double-blind, placebo-controlled study 2012, Abstract of the 14th World Congress on Pain, Milan, PT429.
28. Lassen N.A., Bartenstein P.A., Lammertsma A.A., Prevett M.C., Turton D.R., Luthra S.K., Osman S., Bloomfield P.M., Jones T., Patsalos P.N., O'Connell M.T., Duncan J.S., Andersen Vanggaard Benzodiazepine receptor quantification in vivo in humans using [llC]flumazenil and PET: application of the steady-state principle. J. Cereb. Blood Flow Metab. 1995, 15:152-165.
29. Liefaard L.C., Ploeger B.A., Molthoff C.F.M., Boellaard R., Lammertsma A.A., Meindert Danhof, Voskuyl R.A. Population pharmacokinetic analysis for simultaneous determination of Bmax and KD in vivo by positron emission tomography. Mol. Imaging Biol. 2005, 7:411-421.
30. Lim K.S., Kwon J.S., Jang I.-J., Jeong J.M., Lee J.S., Kim H.W., Kang W.J., Kim J.-R., Cho J.-Y., Kim E., Yoo S.Y., Shin S.-G., Yu K.-S. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin. Pharmacol. Ther. 2007, 81(2).
31. 11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990, 10:740-747.
32. Olsson H., Halldin C., Farde L. Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. NeuroImage 2004, 22:794-803.
33. Patel S., Hamill T.G., Connolly B., Jagoda E., Li W., Gibson R.E. Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. Nucl. Med. Biol. 2007, 34:1009-1017.
34. Roland P.E., Graufelds C.J., Wåhlin L., Ingelman L., Andersson M., Ledberg A., Pedersen J., Åkerman S., Dabringhaus A., Zilles K. Human brain atlas: for high-resolution functional and anatomical mapping. Hum. Brain Mapp. 1994, 1:173-184.
35. Savic R.M., Karlsson M.O. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009, 11(3):558-569.
36. Spooren W.P., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., Porsolt R.D., Gentsch C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 2000, 295(3):1267-1275.
37. Ståhle L., Karlsten R., Jonzon B., Eriksson B., Kågedal M., Dominicus A. Safety evaluation of the mGluR5 antagonists AZD9272, AZD2066 and AZD 2516 in healthy volunteers and patients with neuropathic pain or major depressive disorder 2012, Abstract of the 14th World Congress on Pain, Milan, PT444.
38. Syvanen S., de Lange E.C., Tagawa Y., Schenke M., Molthoff C.F., Windhorst A.D., Lammertsma A.A., Voskuyl R.A. Simultaneous in vivo measurements of receptor density and affinity using [11C]flumazenil and positron emission tomography: comparison of full saturation and steady state methods. NeuroImage 2011, 57:928-937.
39. Tatarczyńska E., Klodzińska A., Chojnacka-Wójcik E., Palucha A., Gasparini F., Kuhn R., Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 2001, 132(7):1423-1430.
40. 11C-ABP688: assessment of methods. J. Nucl. Med. 2007, 48:1207-1215.
41. Varney M.A., Gereau R.W. Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr. Drug Targets CNS Neurol. Disord. 2002, 1(3):283-296.
42. Varrone A., Sjöholm N., Eriksson L., et al. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:1639-1650.
43. Vong C., Bergstrand M., Nyberg J., Karlsson M.O. Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models. AAPS J. 2012, 14(2):176-186.
44. Walker K., Bowes M., Panesar M., Davis A., Gentry C., Kesingland A., Gasparini F., Spooren W., Stoehr N., Pagano A., Flor P.J., Vranesic I., Lingenhoehl K., Johnson E.C., Varney M., Urban L., Kuhn R. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology 2001, 40(1):1-9.
45. Walker K., Reeve A., Bowes M., Winter J., Wotherspoon G., Davis A., Schmid P., Gasparini F., Kuhn R., Urban L. mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology 2001, 40(1):10-19.
46. Zamuner S., Rabiner E.A., Fernandes S.A., Bani M., Gunn R.N., Gomeni R., Ratti E., Cunningham V.J. A pharmacokinetic PET study of NK(1) receptor occupancy. Eur. J. Nucl. Med. Mol. Imaging 2012, 39:226-235.